Investigational drugs for idiopathic pulmonary fibrosis. (2nd September 2017)

• Record Type: Journal Article
• Authors: Varone, Francesco; Montemurro, Giuliano; Macagno, Francesco; Calvello, Mariarosaria; Conte, Emanuele; Intini, Enrica; Iovene, Bruno; Leone, Paolo Maria; Mari, Pier-Valerio; Richeldi, Luca
• Is Part Of: Expert opinion on investigational drugs. Volume 26:Number 9(2017)
• Page Start: 1019
• Page End: 1031
• Publication Date: 2017-09-02
• Subjects: Alveolar epithelial cell -- autoimmunity -- idiopathic pulmonary fibrosis -- immunity -- mesenchyme -- novel targets -- precision medicine -- pulmospheres -- stem cell -- tyrosine-kinase antagonists; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2017.1364361
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : IPF is a specific form of chronic fibrosing interstitial pneumonia of unknown cause, characterized by progressive worsening in lung function and an unfavorable prognosis. Current concepts on IPF pathogenesis are based on a dysregulated wound healing response, leading to an over production of extracellular matrix. Based on recent research however, several other mechanisms are now proposed as potential targets for novel therapeutic strategies. Areas covered : This review analyzes the current investigational strategies targeting extracellular matrix deposition, tyrosine-kinase antagonism, immune and autoimmune response, and cell-based therapy. A description of the pathogenic rationale implied in each novel therapeutic approach is summarized. Expert opinion : New IPF drugs are being evaluated in the context of phase 1 and 2 clinical trials. Nevertheless, many drugs that have shown efficacy in preclinical studies, failed to exhibit the same positive effect when translated to humans. A possible explanation for these failures might be related to the known limitations of animal models of the disease. The recent development of 3D systems composed of cells from individual patients that recreate an ex-vivo model of IPF, could lead to significant improvements in disease pathogenesis and treatment. New drugs could be tested on more genuine models and clinicians could tailor therapy based on patient's response.